Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.35 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982824 | 1.00 | KMT2A (0.41) | KMT2AOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL14343034 | 0.89 | KMT2A (0.42) | KMT2AMAPTHSD11B1 | |
| SCHEMBL4190356 | 0.84 | KMT2A (0.46) | KMT2AOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4750274 | 0.82 | KMT2A (0.40) | KMT2AOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL741948 | 0.81 | KMT2A (0.43) | KMT2AOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL739249 | 0.81 | KMT2A (0.43) | KMT2AOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2670667 | 0.80 | KMT2A (0.35) | KMT2AMAPTALDH1A1MAPK1HSD11B1 | |
| SCHEMBL4748878 | 0.77 | KMT2A (0.41) | KMT2AMAPTMAPK1HSD11B1 | |
| SCHEMBL2670426 | 0.76 | CYP4F2 (0.40) | KMT2AHSD11B1 | |
| SCHEMBL4748042 | 0.75 | KMT2A (0.39) | KMT2AMAPTMAPK1POLBHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563805-B2 | 7-[3-Amino-3,4-dimethylpyrrolidine-1-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid: quinoline bactericide; broad spectrum, strong antibacterial activity for Grampositive/-negative including multiple resistant cocci; side effect reductcion; drug design | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | QTRT1, RRS1, LAS1L | KMT2A 2638/4885OPRM1 606/4885OPRD1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.